Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 15;10(11):446. doi: 10.3390/cancers10110446

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The tumor inhibition of the combined treatment by the systemic administration of ADSC-E7’-eGFP and the protein vaccine. The GFP immunohistochemical staining of (A) the CT26 tumor with or without the systemic administration of ADSC-E7’-eGFP cells; or (B) the LLC1 tumor with or without the systemic administration of ADSC-E7’-eGFP cells. (C) Time course of the experiment. Two representative bioluminescence images of mice subcutaneously injected with (D) 2 × 10⁵ CT26 cells with indicated treatment; or (E) 2 × 10⁵ LLC1 cells with indicated treatment. Tumor volume measurements of syngeneic tumor models were conducted at indicated days after subcutaneous injection of (F) CT26 cells; or (G) LLC1 cells; * p < 0.05, ** p < 0.01; and *** p < 0.001 using two-way ANOVA.

The tumor inhibition of the combined treatment by the systemic administration of ADSC-E7’-eGFP and the protein vaccine. The GFP immunohistochemical staining of (A) the CT26 tumor with or without the systemic administration of ADSC-E7’-eGFP cells; or (B) the LLC1 tumor with or without the systemic administration of ADSC-E7’-eGFP cells. (C) Time course of the experiment. Two representative bioluminescence images of mice subcutaneously injected with (D) 2 × 10⁵ CT26 cells with indicated treatment; or (E) 2 × 10⁵ LLC1 cells with indicated treatment. Tumor volume measurements of syngeneic tumor models were conducted at indicated days after subcutaneous injection of (F) CT26 cells; or (G) LLC1 cells; * p < 0.05, ** p < 0.01; and *** p < 0.001 using two-way ANOVA.